CymaBay Therapeutics Inc. (NASDAQ: CBAY) on January 24, 2023, started off the session at the price of $7.20, soaring 15.89% from the previous trading day. During the day, the shares moved up to $7.825 and dropped to $7.02 before settling in for the closing price of $6.61. Within the past 52 weeks, CBAY’s price has moved between $1.67 and $7.15.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
The company achieved an average annual earnings per share of -71.10%. With a float of $80.92 million, this company’s outstanding shares have now reached $87.80 million.
In an organization with 60 employees, it is important to assess its efficiency.
CymaBay Therapeutics Inc. (CBAY) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of CymaBay Therapeutics Inc. is 0.39%, while institutional ownership is 76.30%. The most recent insider transaction that took place on Jun 06, was worth 100,037. In this transaction Chief Executive Officer of this company bought 51,301 shares at a rate of $1.95, taking the stock ownership to the 171,301 shares.
CymaBay Therapeutics Inc. (CBAY) Performance Highlights and Predictions
As on 6/29/2022, Multinational firm has announced its last quarter scores, in which it reported -$0.31 earnings per share (EPS) for the period falling under the consensus outlook (set at -$0.3) by -$0.01. This company achieved a return on equity of -65.30. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -71.10% per share during the next fiscal year.
CymaBay Therapeutics Inc. (NASDAQ: CBAY) Trading Performance Indicators
CymaBay Therapeutics Inc. (CBAY) is currently performing well based on its current performance indicators. A quick ratio of 12.20 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.25, a number that is poised to hit -0.30 in the next quarter and is forecasted to reach -1.11 in one year’s time.
Technical Analysis of CymaBay Therapeutics Inc. (CBAY)
Let’s dig in a bit further. During the last 5-days, its volume was 2.54 million. That was better than the volume of 1.76 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 77.81%. Additionally, its Average True Range was 0.45.
During the past 100 days, CymaBay Therapeutics Inc.’s (CBAY) raw stochastic average was set at 96.47%, which indicates a significant increase from 92.34% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 77.05% in the past 14 days, which was higher than the 63.60% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.81, while its 200-day Moving Average is $3.50. However, in the short run, CymaBay Therapeutics Inc.’s stock first resistance to watch stands at $7.98. Second resistance stands at $8.31. The third major resistance level sits at $8.79. If the price goes on to break the first support level at $7.18, it is likely to go to the next support level at $6.70. Assuming the price breaks the second support level, the third support level stands at $6.37.
CymaBay Therapeutics Inc. (NASDAQ: CBAY) Key Stats
Market capitalization of the company is 624.37 million based on 84,678K outstanding shares. Right now, sales total 0 K and income totals -90,000 K. The company made 0 K in profit during its latest quarter, and -24,505 K in sales during its previous quarter.